Research article
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
-
* Corresponding author: Debora Williams-Herman debora_williamsherman@merck.com
Merck Research Laboratories, Rahway, NJ USA
BMC Endocrine Disorders 2010, 10:7 doi:10.1186/1472-6823-10-7
Published: 22 April 2010Additional files
Additional file 1:
Supplemental Table S1. Non-malignant adverse events in the Neoplasm SOC. The table lists the types and incidence rates of the non-malignant adverse events.
Format: PDF Size: 83KB Download file
This file can be viewed with: Adobe Acrobat Reader
